Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Common Equity (2023 - 2025)

Upstream Bio (UPB) has 3 years of Common Equity data on record, last reported at $378.6 million in Q3 2025.

  • For Q3 2025, Common Equity rose 336.16% year-over-year to $378.6 million; the TTM value through Sep 2025 reached $378.6 million, up 336.16%, while the annual FY2024 figure was $469.9 million, 481.6% up from the prior year.
  • Common Equity reached $378.6 million in Q3 2025 per UPB's latest filing, down from $408.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $469.9 million in Q4 2024 and bottomed at -$160.3 million in Q3 2024.
  • Average Common Equity over 3 years is $114.1 million, with a median of -$112.2 million recorded in 2023.
  • The widest YoY moves for Common Equity: up 481.6% in 2024, down 42.87% in 2024.
  • A 3-year view of Common Equity shows it stood at -$123.1 million in 2023, then skyrocketed by 481.6% to $469.9 million in 2024, then decreased by 19.42% to $378.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $378.6 million in Q3 2025, $408.7 million in Q2 2025, and $445.6 million in Q1 2025.